Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sinovation Ventures

Founders Hua Wang Lee Kai-Fu

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 368
Average round size
info
The average size of a deal this fund participated in
$22M
Portfolio companies 275
Rounds per year 24.53
Lead investments 56
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 32
Key employees 17
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Software
  • Artificial Intelligence
  • Internet
  • Mobile
  • Education
Summary

Sinovation Ventures appeared to be the VC, which was created in 2009. The main office of represented VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.

The higher amount of exits for fund were in 2018. The fund is constantly included in 13-24 deals per year. Speaking about the real fund results, this VC is 4 percentage points less often commits exit comparing to other organizations. When the investment is from Sinovation Ventures the average startup value is more than 1 billion dollars. Opposing the other organizations, this Sinovation Ventures works on 21 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity.

The current fund was established by Hua Wang, Kai-Fu Lee. We also calculated 20 valuable employees in our database.

Among the most popular fund investment industries, there are Education, Machine Learning. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Bitmain Technologies, Meitu, Vipkid The fund has no exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Sinovation Ventures, startups are often financed by Tencent Holdings, Sequoia Capital China, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Y Combinator, Northern Light Venture Capital, IDG Capital. In the next rounds fund is usually obtained by Northern Light Venture Capital, Innohub Capital, TCL Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sinovation Ventures:
Typical Co-investors
Sinovation Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sinovation Ventures:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Hope Medicine

Health Care
Medical
$30M07 Feb 2024 Xuanwu District, Jiangsu, China

Magair Chemical

Biotechnology
Life Science
Pharmaceutical
$26M09 Jan 2024 Shanghai, Shanghai, China

Heranova Lifesciences

Biotechnology
Health Care
Medical
$3M28 Dec 2023 Huangpu, Shanghai, China

Meson Technology

Biopharma
Chemical
Environmental Consulting
27 Dec 2023 Nanjing, Jiangsu, China

AutoAgents

Information Technology
Software
25 Dec 2023 -

Silicon Mobile Technology

Infrastructure
Software
$7M01 Dec 2023 Haidian, Beijing, China

01.AI

Software
06 Nov 2023 Beijing, Beijing, China

WorkMagic

Information Technology
Marketing
SaaS
$2M24 Oct 2023 Newark, California, United States

Yixinshang Technology

Consulting
Employee Benefits
Enterprise Software
SaaS
19 Oct 2023 Beijing, Beijing, China
News
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus

– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing

– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sinovation Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 368
Average round size 22M
Rounds per year 24.53
Peak activity year 2014
Lead investments 56
Follow on index 0.25
Exits 32
Group Appearance index 0.70

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Hope Medicine

Health Care
Medical
$30M07 Feb 2024 Xuanwu District, Jiangsu, China

Magair Chemical

Biotechnology
Life Science
Pharmaceutical
$26M09 Jan 2024 Shanghai, Shanghai, China

Heranova Lifesciences

Biotechnology
Health Care
Medical
$3M28 Dec 2023 Huangpu, Shanghai, China

Meson Technology

Biopharma
Chemical
Environmental Consulting
27 Dec 2023 Nanjing, Jiangsu, China

AutoAgents

Information Technology
Software
25 Dec 2023 -

Silicon Mobile Technology

Infrastructure
Software
$7M01 Dec 2023 Haidian, Beijing, China

01.AI

Software
06 Nov 2023 Beijing, Beijing, China

WorkMagic

Information Technology
Marketing
SaaS
$2M24 Oct 2023 Newark, California, United States

Yixinshang Technology

Consulting
Employee Benefits
Enterprise Software
SaaS
19 Oct 2023 Beijing, Beijing, China
Crunchbase icon

Content report

The following text will be sent to our editors: